These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 36181401

  • 1. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM, Syam AF, Lee YY.
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
    Kanu JE, Soldera J.
    World J Gastroenterol; 2024 Mar 07; 30(9):1213-1223. PubMed ID: 38577188
    [Abstract] [Full Text] [Related]

  • 3. Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis.
    Simadibrata DM, Lesmana E, Pratama MIA, Sugiharta AJ, Kalaij AGI, Fadhilla ADD, Danpanichkul P, Syam AF, Simadibrata M.
    Dig Dis Sci; 2024 Oct 07; 69(10):3863-3874. PubMed ID: 39294424
    [Abstract] [Full Text] [Related]

  • 4. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM, Lesmana E, Fass R.
    J Gastroenterol Hepatol; 2024 May 07; 39(5):796-805. PubMed ID: 38263507
    [Abstract] [Full Text] [Related]

  • 5. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, Li YQ.
    Dig Dis Sci; 2018 Feb 07; 63(2):302-311. PubMed ID: 29282636
    [Abstract] [Full Text] [Related]

  • 6. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct 07; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 7. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H.
    Helicobacter; 2018 Aug 07; 23(4):e12495. PubMed ID: 29873436
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
    Zhang M, Pang M, Zhang M.
    Clinics (Sao Paulo); 2022 Aug 07; 77():100058. PubMed ID: 35810638
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, Fujita M, Okada A.
    Digestion; 2017 Aug 07; 96(1):52-59. PubMed ID: 28662503
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL, Lin BS, Li YY, Ding YM, Han ZX, Ji R.
    Digestion; 2023 Aug 07; 104(4):249-261. PubMed ID: 37015201
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H.
    J Clin Pharm Ther; 2022 Jul 07; 47(7):897-904. PubMed ID: 35247003
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis.
    Zhou X, Duan H, Li Q, Wang Q, Sun X.
    Scand J Gastroenterol; 2024 Jul 07; 59(7):788-797. PubMed ID: 38741565
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication.
    Nabeta H, Shinozaki S, Abe Y, Koyanagi R, Nakamichi T, Kobayashi Y, Lefor AK, Hirashima H.
    Digestion; 2020 Jul 07; 101(3):332-338. PubMed ID: 30991394
    [Abstract] [Full Text] [Related]

  • 18. Vonoprazan: A Review in Helicobacter pylori Infection.
    Shirley M.
    Drugs; 2024 Mar 07; 84(3):319-327. PubMed ID: 38388872
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.